Dolby Laboratories DLB
58.56
1.00
1.74%
as of 25 Sep
- Market cap
- $5.4B
- P/E
- 24.6×
Follow DLB
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
27.21 | 25.59 | 23.46 | 22.09 |
P/S ratio |
5.14 | 4.58 | 4.19 | 3.66 | |
P/FCF ratio |
16.13 | 15.87 | 21.60 | 13.72 | |
P/Operating CF |
56.48 | 111.88 | 61.82 | 29.59 | |
P/B ratio |
2.64 | 2.36 | 2.18 | 1.91 | |
Price to Tangible BV |
4.07 | 3.59 | 3.35 | 2.95 | |
EV/Sales |
4.55 | 4.04 | 3.70 | 3.11 | |
EV/EBITDA |
16.90 | 15.55 | 14.21 | 12.31 | |
EV/Operating CF |
13.01 | 12.86 | 14.93 | 9.63 | |
EV/FCF |
14.28 | 13.99 | 19.06 | 11.67 | |
Quick Ratio |
2.57 | 2.48 | 2.25 | 2.46 | |
Current Ratio |
3.17 | 3.17 | 2.98 | 3.19 | |
Net Debt/EBITDA |
(14.64) | (8.19) | (4.82) | (12.45) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.43 | 0.42 | 0.42 | 0.43 | |
Operating CF/Net income |
2.49 | 1.03 | 0.97 | 5.85 | |
Capex/Depreciation |
(0.89) | 0.05 | (1.72) | (0.39) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
21.97% | 19.92% | 16.09% | 21.56% | |
Selling, General and Administrative Expense of Revenue |
53.49% | 46.67% | 43.50% | 52.67% | |
Intangible Assets out of Total Assets |
0.29 | 0.28 | 0.28 | 0.29 | |
Share Based Compensation of Revenue |
10.11% | 10.73% | 7.76% | 10.15% | |
Graham Net Nets |
0.11 | 0.13 | 0.14 | 0.15 | |
Graham Number |
40.54 | 39.24 | 39.87 | 38.38 | |
Earnings Yield |
3.68% | 3.91% | 4.26% | 4.53% | |
Free Cash Flow Yield |
6.20% | 6.30% | 4.63% | 7.29% | |
Revenue per Share |
3.20 | 3.63 | 4.16 | 3.24 | |
Operating CF per Share |
1.28 | 0.57 | 0.97 | 1.78 | |
Capex per Share |
(0.23) | 0.01 | (0.48) | (0.10) | |
Free Cash Flow per Share |
1.05 | 0.59 | 0.49 | 1.67 | |
Cash per Share |
8.28 | 7.63 | 7.08 | 7.85 | |
Shareholders Equity per Share |
27.45 | 27.26 | 27.59 | 27.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
27.45 | 27.26 | 27.59 | 27.51 | |
Free Cash Flow |
100.99 | 56.04 | 46.42 | 157.67 | |
Working Capital |
950.47 | 964.56 | 940.10 | 909.71 | |
Capital Expenditures |
(21.84) | 1.25 | (46.09) | (9.79) | |
Net Current Asset Value |
792.45 | 818.81 | 792.35 | 762.15 | |
EV/EBIT |
23.19 | 21.85 | 19.98 | 17.63 | |
Capex to Sales |
0.07 | 0.00 | 0.12 | 0.03 | |
Net Profit Margin |
16.07% | 15.38% | 23.99% | 9.38% | |
Price to Operating Income |
26.19 | 24.80 | 22.66 | 20.72 | |
| Other line items | |||||
Average Receivables |
323.28 | 356.20 | 352.70 | 291.38 | |
Average Payables |
17.61 | 10.11 | 18.99 | 14.85 | |
Average Inventory |
32.08 | 31.55 | 33.26 | 31.59 | |
Average Assets |
3,168.84 | 3,175.36 | 3,239.27 | 3,176.30 | |
Average Common Equity |
2,559.42 | 2,559.95 | 2,605.08 | 2,603.48 |
Columns are period end dates